Banco Bradesco just surged 18.8%—and the story goes well beyond politics. We revisit BBD after first turning bullish at $3.45, examining 10 straight quarters of improving profits, its R$10B capital raise, insider alignment, income potential and the seismic repricing of Brazilian banks and fintech.

Read entire article

Eight Star Bulk insiders acquired roughly $6.9 million of SBLK at $28.27 as Q2 net income reached $144.9 million and the board declared a $0.90 dividend. At just 7.2x forward earnings, is this dry-bulk giant genuinely cheap—or simply enjoying the favorable side of a notoriously brutal shipping cycle?

Read entire article

Aon Chairman Lester Knight just bought roughly $6.5 million of AON stock after the company announced its massive $17 billion USI acquisition. The insider signal is compelling—but with leverage headed toward 4.8×, buybacks paused and integration risk rising, is AON finally cheap enough?

Read entire article

DICK’S Sporting Goods plunged roughly 30% as Foot Locker weakness rattled Wall Street. Then three directors bought $2.94 million. With core DICK’S comps up 4.9%, operating cash flow at $792 million and the stock at 9.3x forward earnings, is Wall Street pricing temporary integration pain like permanent deterioration?

Read entire article

Zoetis (ZTS) may be one of the most interesting “quality in the doghouse” setups of 2026. The global animal-health leader is still profitable, institutionally loved, and backed by powerful pet-humanization trends — yet soft U.S. pet spending, competition, and lowered guidance have crushed the stock. With directors buying near the lows and forward P/E near 11x, is ZTS finally becoming a value play?

Read entire article

Primo Brands isn't simply selling bottled water.

It's quietly building one of North America's largest hydration infrastructure platforms.

With repeat CEO insider buying, nearly $800 million in annual free cash flow, raised guidance, and exceptional institutional ownership, PRMB deserves a closer look.

Read entire article

Pfizer has spent years under pressure following the collapse of pandemic-era revenues. Yet beneath the headlines, the company's non-COVID business is strengthening, oncology is expanding through Seagen, and two highly respected directors—including former Vanguard CEO and CIO Tim Buckley—recently invested nearly $2 million of their own money. We examine whether Wall Street is overlooking one of healthcare's most compelling value opportunities.

Read entire article

Bunge isn't merely a grain trader—it's one of the world's most important agricultural infrastructure companies. After a 43% rally from our 2025 recommendation, a healthy pullback, another insider purchase, stronger earnings guidance and accelerating Viterra synergies make the long-term investment story compelling once again.

Read entire article

Huntsman isn't simply a cyclical chemical company anymore. Between repeated insider buying, a transformational $12.5 billion merger with Olin, trading at just 0.64x book value and more than $400 million in projected synergies, investors may be looking at one of the market's more intriguing industrial turnaround opportunities.

Read entire article

Conagra's 50% dividend cut shocked income investors—but the story didn't end there. With CEO John Brase buying more than $510,000 of stock, debt moving lower, and shares trading around 10x forward earnings, the turnaround thesis deserves another look.

Read entire article